Market Research Reports

Meningococcal Vaccines Market (Polysaccharide, Conjugate, Combination and Men B Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022

117pages
Published Date: 2015-05-07

Description



Meningococcal disease, especially meningococcal meningitis, is one of the most catastrophic infections among individuals or communities. Several meningococcal serogroups have been identified till date, of which serogroups A, B, C, Y, and W-135 are the most prominent ones causing the infection. Meningococcal disease is a life threatening condition and potentially fatal illness caused due to the bacterium Neisseria meningitidis. It causes serious infection of the thin layers of connective tissue surrounding the brain and spinal cord called the meninges. Immunization by vaccines has been of great help to public health. It has saved millions of children and provided them with a chance of better and healthier life. Many diseases have been eradicated, while some have been better controlled. Thus vaccines are considered as the most powerful form of all preventive measures. Meningococcal disease is one such disease which has a high mortality rate if left undiagnosed and untreated. Meningococcal vaccines are used to prevent diseases such as meningitis, meningococcemia and septicemia, caused due to N. meningitidis.

According to a report by CDC, incidences of bacterial meningitis have dropped by almost a third over the past decade due to stringent regulations, awareness and initiatives taken by the government as well as the citizens. The global meningococcal vaccines market is studied on the basis of vaccine types such as polysaccharide, conjugate, and combination vaccines that are further segmented into different brands. The report also highlights and analyzes various brands of Men B vaccines recently approved, such as Bexsero and Trumenba, as well as the vaccine currently in pipeline - NmVac-4DT. A detailed market analysis and forecast for these segments has been provided in this study, in terms of revenue (USD million) for the period 2012 to 2022. The report also provides the compounded annual growth rate (CAGR %) for each meningococcal vaccine segment and brand for the forecast period 2014 to 2022, while market size estimations have been made considering 2012 and 2013 as the base years. 

In terms of geographical distribution, the global meningococcal vaccines market has been classified into four major geographical areas, namely North America, Europe, Asia-Pacific and Rest of the World (RoW). The regions are further broken down by major countries. The current and future market sizes (in terms of USD million) of the mentioned regional markets and their major countries have been provided in the report for the period 2012 to 2022 with their growth rate (%) for the period 2014 to 2022. The study further offers recommendations and highlights of the market, which would be useful for the current and future market players to sustain and flourish in the global meningococcal vaccines market. 

The global meningococcal vaccines market overview section of the report demonstrates the market dynamics and market trends such as drivers, restraints and opportunities that influence the current and future status of meningococcal vaccines industry. Impact factors such as market attractiveness analysis and Porter’s five forces analysis have also been explained in the market overview section of the global meningococcal vaccines report, in order to give a thorough analysis of the overall competitive scenario in the global meningococcal vaccines market. The global meningococcal vaccines market report also covers qualitative information on certain areas in market overview section which include clinical features, epidemiology, diagnosis and treatment for meningococcal disease, types of meningococcal vaccines, and regulatory scenario. 

The report concludes with the company profiles section which includes key information about the major players in this market. Key players profiled in this report include Sanofi S.A., Novartis International AG, GlaxoSmithKline plc, Pfizer, Inc., Serum Institute of India, Ltd., JN-International Medical Corporation, Nuron Biotech, Baxter International and Biomed Pvt. Ltd.

The global meningococcal vaccines market is segmented as follow:

Meningococcal Vaccines Market, by Type
  • Polysaccharide Vaccines, by Brand
    • Menomune
    • Mencevax
    • NmVac4
    • Others
      • Quadri Meningo
      • Bi Meningo
  • Conjugate Vaccines, by Brand
    • Menactra
    • Menveo
    • NeisVac-C
    • Nimenrix
    • Meningitec
    • Menjugate
    • MenAfriVac
    • NmVac4-DT
  • Combination Vaccines, by Brand
    • MenHibrix
    • Menitorix
  • Men B Vaccines, by Brand
    • Bexsero
    • Trumenba
Meningococcal Vaccines Market, by Geography
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • Africa
    • Rest of RoW

Table of Contents



Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Secondary Research
1.3.2 Primary Research
1.4 List of Abbreviations
1.5 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Meningococcal Vaccines Market (2013 & 2022)
2.2 Global Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
2.3 Comparative Analysis: Global Meningococcal Vaccines Market, by Geography, 2013 & 2022 (Value %)

Chapter 3 Global Meningococcal Vaccines Market Overview
3.1 Introduction
     3.1.1 Meningococcal Disease
            3.1.1.1 Risk Factors for Meningococcal Disease
            3.1.1.2 Clinical Features
                      3.1.1.2.1 Clinical Manifestations of Meningococcal Disease
            3.1.1.3 Epidemiology
            3.1.1.4 Diagnosis & Treatment
     3.1.2 Types of Meningococcal Vaccines
             3.1.2.1 Major Marketed Meningococcal Vaccines
3.2 Regulatory Scenario
     3.2.1 Meningococcal Vaccines in Pipeline
3.3 Market Drivers
     3.3.1 Developing economies reshaping global health and development
     3.3.2 Education and awareness through various non-profit organizations
     3.3.3 Travel vaccines for meningococcal disease
3.4 Market Restraints
     3.4.1 Disparate age groups and dosage regimen for routine immunization, and unpredictable and dynamic epidemiology of meningococcal disease
     3.4.2 Maintenance of cold chains to deliver vaccines leading to high cost of vaccination
3.5 Market Opportunities
     3.5.1 Development of vaccines through collaborations and public private partnerships making vaccines more affordable
     3.5.2 Novel approaches to improve the stability of meningococcal vaccines
     3.5.3 Developing halal vaccines
3.6 Event Impact Analysis
3.7 Porter’s Five Force Analysis for the Global Meningococcal Vaccines Market
     3.7.1 Bargaining Power of Suppliers
     3.7.2 Bargaining Power of Buyers
     3.7.3 Threat of Substitutes
     3.7.4 Threat of New Entrants
     3.7.5 Competitive Rivalry
3.8 Market Attractiveness Analysis for the Global Meningococcal Vaccines Market, by Geography

Chapter 4 Global Meningococcal Vaccines Market, by Type
4.1 Introduction
     4.1.1 Global Meningococcal Vaccines Market Revenue, by Type, 2012 - 2022 (USD Million)
4.2 Comparative Analysis: Global Meningococcal Vaccines Market, by Type, 2013 & 2022 (Value %)
     4.2.1 Comparative Analysis: Global Meningococcal Vaccines Market, by Type, 2013 & 2022
4.3 Polysaccharide Meningococcal Vaccines
     4.3.1 Global Polysaccharide Vaccines Market Revenue, by Brand, 2012 - 2022 (USD Million)
     4.3.2 Menomune
             4.3.2.1 Global Menomune Market Revenue, 2012 - 2022 (USD Million)
     4.3.3 Mencevax
            4.3.3.1 Global Mencevax Market Revenue, 2012 – 2022 (USD Million)
     4.3.4 NmVac4-A/C/Y/W-135
            4.3.4.1 Global NmVac4 Market Revenue, 2012 – 2022 (USD Million)
     4.3.5 Others (Bi Meningo, Quadri Meningo)
            4.3.5.1 Global Other Polysaccharide Vaccines Market Revenue, 2012 – 2022 (USD Million)
4.4 Conjugate Meningococcal Vaccines
     4.4.1 Global Conjugate Vaccines Market Revenue, by Brand, 2012 – 2022 (USD Million)
     4.4.2 Menactra
            4.4.2.1 Global Menactra Market Revenue, 2012 – 2022 (USD Million)
     4.4.3 Menveo
            4.4.3.1 Global Menveo Market Revenue, 2012 – 2022 (USD Million)
     4.4.4 NeisVac-C
            4.4.4.1 Global NeisVac-C Market Revenue, 2012 – 2022 (USD Million)
     4.4.5 Nimenrix
            4.4.5.1 Global Nimenrix Market Revenue, 2012 – 2022 (USD Million)
     4.4.6 Meningitec
            4.4.6.1 Global Meningitec Market Revenue, 2012 – 2022 (USD Million)
     4.4.7 Menjugate (Meningococcal Group C- CRM197 Conjugate Vaccine)
            4.4.7.1 Global Menjugate Market Revenue, 2012 – 2022 (USD Million)
     4.4.8 MenAfriVac
            4.4.8.1 Global MenAfriVac Market Revenue, 2012 – 2022 (USD Million)
     4.4.9 NmVac4-A/C/Y/W-135-DT (Nm-Vac4-DT)
            4.4.9.1 Global NmVac4 DT Market Revenue, 2016 – 2022 (USD Million)
4.5 Combination Meningococcal Vaccines
     4.5.1 Global Combination Vaccines Market Revenue, by Brand, 2012 - 2022 (USD Million)
     4.5.2 MenHibrix
            4.5.2.1 Global MenHibrix Market Revenue, 2014 – 2022 (USD Million)
     4.5.3 Menitorix
            4.5.3.1 Global Menitorix Market Revenue, 2012 - 2022 (USD Million)
4.6 Meningococcal B Vaccines
     4.6.1 Bexsero
            4.6.1.1 Global Bexsero Market Revenue, 2014 - 2022 (USD Million)
     4.6.2 Trumenba (MnB rLP2806)
            4.6.2.1 Global Trumenba Market Revenue, 2015 - 2022 (USD Million)

Chapter 5 Global Meningococcal Vaccines Market, by Geography
5.1 Introduction
     5.1.1 Global Meningococcal Vaccines Market Revenue, by Geography, 2012 - 2022 (USD Million)
5.2 North America
     5.2.1 North America Meningococcal Vaccines Market Revenue, by Country, 2012 - 2022 (USD Million)
     5.2.2 U.S.
            5.2.2.1 U.S. Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
     5.2.3 Canada
            5.2.3.1 Canada Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
5.3 Europe
     5.3.1 Europe Meningococcal Vaccines Market Revenue, by Country, 2012 - 2022 (USD Million)
     5.3.2 U.K.
             5.3.2.1 U.K. Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
     5.3.3 Germany
             5.3.3.1 Germany Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
     5.3.4 Rest of Europe
             5.3.4.1 Rest of Europe Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
5.4 Asia-Pacific
     5.4.1 Asia Pacific Meningococcal Vaccines Market Revenue, by Country, 2012 - 2022 (USD Million)
     5.4.2 Japan
            5.4.2.1 Japan Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
     5.4.3 Australia
            5.4.3.1 Australia Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
     5.4.4 Rest of Asia Pacific
             5.4.4.1 Rest of Asia Pacific Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
5.5 Rest of the World
     5.5.1 Rest of the World Meningococcal Vaccines Market Revenue, by Country, 2012 - 2022 (USD Million)
     5.5.2 Latin America
            5.5.2.1 Latin America Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
     5.5.3 Africa
            5.5.3.1 Africa Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
     5.5.4 Rest of RoW
            5.5.4.1 Rest of RoW Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)

Chapter 6 Competitive Landscape
6.1 Market Share by Key Players, 2013 (Value %)
     6.1.1 Methodology
     6.1.2 Analysis

Chapter 7 Recommendations
7.1 Focus on Low Cost of Manufacturing
7.2 Developing Animal Component Free and Halal Vaccines
7.3 Tapping Emerging Markets
7.4 Collaborating With Community Pharmacies

Chapter 8 Company Profiles
8.1 Baxter International, Inc.
     8.1.1 Company Overview
     8.1.2 Financial Overview
     8.1.3 Product Portfolio
     8.1.4 Business Strategies
     8.1.5 Recent Developments
8.2 Biomed Pvt., Ltd.
     8.2.1 Company Overview
     8.2.2 Financial Overview
     8.2.3 Product Portfolio
     8.2.4 Business Strategies
     8.2.5 Recent Developments
8.3 GlaxoSmithKline plc
     8.3.1 Company Overview
     8.3.2 Financial Overview
     8.3.3 Product Portfolio
     8.3.4 Business Strategies
     8.3.5 Recent Developments
8.4 JN-International Medical Corporation
     8.4.1 Company Overview
     8.4.2 Financial Overview
     8.4.3 Product Portfolio
     8.4.4 Business Strategies
     8.4.5 Recent Developments
8.5 Nuron Biotech, Inc.
     8.5.1 Company Overview
     8.5.2 Financial Overview
     8.5.3 Product Portfolio
     8.5.4 Business Strategies
     8.5.5 Recent Developments
8.6 Pfizer, Inc.
     8.6.1 Company Overview
     8.6.2 Financial Overview
     8.6.3 Product Portfolio
     8.6.4 Business Strategies
     8.6.5 Recent Developments
8.7 Sanofi SA
     8.7.1 Company Overview
     8.7.2 Financial Overview
     8.7.3 Product Portfolio
     8.7.4 Business Strategies
     8.7.5 Recent Developments
8.8 Serum Institute of India, Ltd.
     8.8.1 Company Overview
     8.8.2 Financial Overview
     8.8.3 Product Portfolio
     8.8.4 Business Strategies
     8.8.5 Recent Developments

List of Figures

FIG. 1 Global Meningococcal Vaccines Market Segmentation
FIG. 2 Global Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 3 Comparative Analysis: Global Meningococcal Vaccines Market Revenue, by Geography, 2013 & 2022 (Value %)
FIG. 4 Risk Factors for Meningococcal Disease
FIG. 5 Clinical Manifestations of Meningococcal Disease
FIG. 6 Porter’s Five Forces Analysis: Global Meningococcal Vaccines Market
FIG. 7 Market Attractiveness Analysis: Global Meningococcal Vaccines Market, by Geography
FIG. 8 Comparative Analysis: Global Meningococcal Vaccines Market, by Type, 2013 & 2022 (Value %)
FIG. 9 Global Menomune Market Revenue, 2012 – 2022 (USD Million)
FIG. 10 Global Mencevax Market Revenue, 2012 – 2022 (USD Million)
FIG. 11 Global NmVac4 Market Revenue, 2012 – 2022 (USD Million)
FIG. 12 Global Other Polysaccharide Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 13 Global Menactra Market Revenue, 2012 – 2022 (USD Million)
FIG. 14 Global Menveo Market Revenue, 2012 – 2022 (USD Million)
FIG. 15 Global NeisVac-C Market Revenue, 2012 – 2022 (USD Million)
FIG. 16 Global Nimenrix Market Revenue, 2012 – 2022 (USD Million)
FIG. 17 Global Meningitec Market Revenue, 2012 – 2022 (USD Million)
FIG. 18 Global Menjugate Market Revenue, 2012 – 2022 (USD Million)
FIG. 19 Global MenAfriVac Market Revenue, 2012– 2022 (USD Million)
FIG. 20 Global NmVac4 DT Market Revenue, 2016 – 2022 (USD Million)
FIG. 21 Global MenHibrix Market Revenue, 2014 – 2022 (USD Million)
FIG. 22 Global Menitorix Market Revenue, 2012 – 2022 (USD Million)
FIG. 23 Global Bexsero Market Revenue, 2014 – 2022 (USD Million)
FIG. 24 Global Trumenba Market Revenue, 2015 – 2022 (USD Million)
FIG. 25 U.S. Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 26 Canada Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 27 U.K. Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 28 Germany Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 29 Rest of Europe Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 30 Japan Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 31 Australia Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 32 Rest of Asia Pacific Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 33 Latin America Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 34 Africa Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 35 Rest of RoW Meningococcal Vaccines Market Revenue, 2012 – 2022 (USD Million)
FIG. 36 Market Share Analysis: Global Meningococcal Vaccines Market, 2013 (Value %)
FIG. 37 Baxter International, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 38 GlaxoSmithKline plc: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 39 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 40 Sanofi SA: Annual Revenue, by Segment, 2011 – 2013 (USD Million)

List of Tables

TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Global Meningococcal Vaccines Market (2013 & 2022)
TABLE 3 Major Marketed Meningococcal Vaccines
TABLE 4 Meningococcal Vaccines in Pipeline
TABLE 5 Event Impact Analysis
TABLE 6 Global Meningococcal Vaccines Market Revenue, by Type, 2012 - 2022 (USD Million)
TABLE 7 Global Polysaccharide Vaccines Market Revenue, by Brand, 2012 – 2022 (USD Million)
TABLE 8 Global Conjugate Vaccines Market Revenue, by Brand, 2012 – 2022 (USD Million)
TABLE 9 Global Combination Vaccines Market Revenue, by Brand, 2012 - 2022 (USD Million)
TABLE 10 Global Meningococcal Vaccines Market Revenue, by Geography, 2012 - 2022 (USD Million)
TABLE 11 North America Meningococcal Vaccines Market Revenue, by Country, 2012 - 2022 (USD Million)
TABLE 12 Europe Meningococcal Vaccines Market Revenue, by Country, 2012 - 2022 (USD Million)
TABLE 13 Asia Pacific Meningococcal Vaccines Market Revenue, by Country, 2012 - 2022 (USD Million)
TABLE 14 Rest of the World Meningococcal Vaccines Market Revenue, by Country, 2012 - 2022 (USD Million)

Free Market Analysis



Meningococcal disease caused by the bacterium Neisseria meningitidis is a life threatening condition which severely infects the meninges or the thin lining surrounding the brain and the spinal cord. Five out of many serogroups of the bacterium are responsible for the invasive meningococcal disease. These serogroups are predominantly present only in humans in the dormant state and may eventually cause the diseased condition due to environmental or immunogenic factors. The disease is known to be contagious and its consequences can be fatal within 24 hours from the onset of symptoms. Prevalence of the serogroups responsible for the disease varies with age, time and geographical locations. The global market for meningococcal vaccines was valued at USD 1,537.3 million in 2013 and is expected to reach USD 4,450.4 million in 2022 at a CAGR of 12.4 % from 2014 - 2022.

The global meningococcal vaccines market is segmented broadly into polysaccharide, conjugate, combination and Men B vaccines. These vaccine types are further segmented into different brands available in the market. Polysaccharide vaccines is the oldest type available in market since last three decades. However, the presence and widespread use of conjugate vaccines has drastically reduced the incidences of bacterial meningitis due to the prolonged immunity achieved against the disease-causing serogroups, unlike polysaccharide vaccines which provide immunity for a very short period. Combination vaccines against invasive meningococci in combination with other organisms such as pneumococcal and Haemophilus influenzae type B are considered as new weapons to fight against two bacterial infections. This has shown to reduce the number of injections needed to be administered when compared to their individual doses.

Recently approved Men B vaccines include Bexsero by Novartis, and Trumenba by Pfizer. The U.S. FDA approved Bexsero in January 2015 and Trumenba in October 2014. In January 2013, Novartis received marketing authorization for Bexsero as the only vaccine against serogroup B, across the European Union, Canada and Australia, and has been currently filed for U.S. FDA licensure. The notable pipeline conjugate vaccine against meningococcal disease includes NmVac4-DT by JN International Medical Corporation. NmVac4 DT has been developed against the broad range of (quadrivalent) serogroups A, C, Y and W-135. Moreover, JN- International claims the vaccine to be animal component free, which is expected to be the major driver for its demand post market launch.

Major growth drivers for the global meningococcal vaccines market include favourable public-private partnerships to support development of vaccines at low cost, and the medical emergency status of the disease. Increase in the demand for vaccines and also the number of people getting immunized has been majorly contributed to the education and awareness campaigns conducted by manufacturers as well as non-profit organizations in the developed economies. Government intervention such as approval of legislations to mandate immunization programs for school children up to a certain age, and stringent regulations for Hajj pilgrims and sub-Saharan travellers also contribute positively to this market due to increased demand for these vaccines from the non-profit organizations.

Geographically, North America is the largest market in terms of revenue in 2013. In North America and Europe, due to government intervention with respect to legislations, immunization programs and awareness campaigns incidences of meningitis have reduced to a large extent. According to a report by the U.S. Centers for Disease Control and Prevention (CDC) 1,000 to 2,600 people contract meningococcal disease each year in the United States, whereas in Africa, it is estimated to be 1,000 cases per 100,000 population. Asia Pacific is expected to be the fastest growing market followed by Rest of the World (RoW) during the forecast period. Factors driving the market in this region include the continuous growth in the population base, the cyclic occurrences of meningococcal disease outbreaks in past and the rising focus on preventive measure against the dreadful disease. The onset of recent trends such as enrolment of pharmacists in training programs conducted by New Zealand Ministry of Health is also contributing to the market growth. 

The key players contributing to the global meningococcal vaccines market include Sanofi SA, Novartis AG, GSK plc, Pfizer, Inc., Nuron Biotech, JN International Medical Corporation, Serum Institute of India Ltd., Baxter International and Biomed Pvt. Ltd.

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Report tailored as you need

If you feel this report needs customization, feel free to contact us. Our team of expert analyst can fulfil your requirements.

CUSTOMIZE REPORT

Upcoming Report

Payment
Copyright @ Transparency Market Research